Outcome of allogeneic hematopoietic stem cell transplantation for mycosis fungoides and Sézary syndrome

Takehiko Mori, Souichi Shiratori, Junji Suzumiya, Mineo Kurokawa, Motohiro Shindo, Uchida Naoyuki, Takenaka Katsuto, Toshihiro Miyamoto, Satoshi Morishige, Makoto Hirokawa, Takahiro Fukuda, Yoshiko Atsuta, Ritsuro Suzuki

研究成果: ジャーナルへの寄稿学術誌査読

9 被引用数 (Scopus)


Although allogeneic hematopoietic stem cell transplantation (HSCT) has been reported to provide prolonged remission of relapsed/refractory mycosis fungoides (MF) and Sézary syndrome (SS), its role has not been fully evaluated. Here, the outcomes of allogeneic HSCT for patients with MF/SS were retrospectively evaluated by using the registry database of the Japan Society for Hematopoietic Cell Transplantation. Forty-eight patients were evaluable and enrolled in the analysis. Median age was 45.5 years. Eighteen patients (38%) received myeloablative conditioning, and 33 (69%) received HSCT from an alternative donor. Disease status was complete or partial response in 25% of the patients and relapsed or refractory in the others. At the time of analysis, 18 patients were alive, with a median follow-up of 31.0 months (range, 3.8-31.1). Three-year overall survival (OS) and progression-free survival (PFS) were 30% (95%CI, 16-45%) and 19% (95%CI, 9-31%), respectively. Disease progression was not observed later than 17 months after transplantation. Both disease status and performance status at transplant significantly affected OS and PFS. Although our findings suggest that allogeneic HSCT provides long-term PFS in patients with MF/SS, the timing of transplantation should be decided carefully based on the disease status and the patient's condition in order to improve the outcome.

ジャーナルHematological Oncology
出版ステータス出版済み - 8月 1 2020

!!!All Science Journal Classification (ASJC) codes

  • 血液学
  • 腫瘍学
  • 癌研究


「Outcome of allogeneic hematopoietic stem cell transplantation for mycosis fungoides and Sézary syndrome」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。